Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Viral genome wide association study identifies novel hepatitis C virus polymorphisms associated with sofosbuvir treatment failure

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{9001d7174ac5489cb2a655c2abd96fba,
title = "Viral genome wide association study identifies novel hepatitis C virus polymorphisms associated with sofosbuvir treatment failure",
abstract = "Persistent hepatitis C virus (HCV) infection is a major cause of chronic liver disease, worldwide. With the development of direct-acting antivirals, treatment of chronically infected patients has become highly effective, although a subset of patients responds less well to therapy. Sofosbuvir is a common component of current de novo or salvage combination therapies, that targets the HCV NS5B polymerase. We use pre-treatment whole-genome sequences of HCV from 507 patients infected with HCV subtype 3a and treated with sofosbuvir containing regimens to detect viral polymorphisms associated with response to treatment. We find three common polymorphisms in non-targeted HCV NS2 and NS3 proteins are associated with reduced treatment response. These polymorphisms are enriched in post-treatment HCV sequences of patients unresponsive to treatment. They are also associated with lower reductions in viral load in the first week of therapy. Using in vitro short-term dose-response assays, these polymorphisms do not cause any reduction in sofosbuvir potency, suggesting an indirect mechanism of action in decreasing sofosbuvir efficacy. The identification of polymorphisms in NS2 and NS3 proteins associated with poor treatment outcomes emphasises the value of systematic genome-wide analyses of viruses in uncovering clinically relevant polymorphisms that impact treatment.",
keywords = "Antiviral Agents/therapeutic use, Genome, Viral/genetics, Genotype, Hepacivirus/drug effects, Hepatitis C, Chronic/drug therapy, Humans, Polymorphism, Genetic, Sofosbuvir/therapeutic use, Treatment Failure, Viral Load/drug effects, Viral Nonstructural Proteins/genetics",
author = "Smith, {David A} and Carlota Fernandez-Antunez and Andrea Magri and Rory Bowden and Nimisha Chaturvedi and Jacques Fellay and John McLauchlan and Foster, {Graham R} and Irving, {William L} and Peter Simmonds and Vincent Pedergnana and Santseharay Ramirez and Jens Bukh and Eleanor Barnes and Ansari, {M Azim} and {STOP-HCV Consortium}",
note = "{\textcopyright} 2021. The Author(s).",
year = "2021",
month = oct,
day = "20",
doi = "10.1038/s41467-021-25649-6",
language = "English",
volume = "12",
pages = "1--11",
journal = "Nature Communications",
issn = "2041-1723",
publisher = "Nature Publishing Group",
number = "1",

}

RIS

TY - JOUR

T1 - Viral genome wide association study identifies novel hepatitis C virus polymorphisms associated with sofosbuvir treatment failure

AU - Smith, David A

AU - Fernandez-Antunez, Carlota

AU - Magri, Andrea

AU - Bowden, Rory

AU - Chaturvedi, Nimisha

AU - Fellay, Jacques

AU - McLauchlan, John

AU - Foster, Graham R

AU - Irving, William L

AU - Simmonds, Peter

AU - Pedergnana, Vincent

AU - Ramirez, Santseharay

AU - Bukh, Jens

AU - Barnes, Eleanor

AU - Ansari, M Azim

AU - STOP-HCV Consortium

N1 - © 2021. The Author(s).

PY - 2021/10/20

Y1 - 2021/10/20

N2 - Persistent hepatitis C virus (HCV) infection is a major cause of chronic liver disease, worldwide. With the development of direct-acting antivirals, treatment of chronically infected patients has become highly effective, although a subset of patients responds less well to therapy. Sofosbuvir is a common component of current de novo or salvage combination therapies, that targets the HCV NS5B polymerase. We use pre-treatment whole-genome sequences of HCV from 507 patients infected with HCV subtype 3a and treated with sofosbuvir containing regimens to detect viral polymorphisms associated with response to treatment. We find three common polymorphisms in non-targeted HCV NS2 and NS3 proteins are associated with reduced treatment response. These polymorphisms are enriched in post-treatment HCV sequences of patients unresponsive to treatment. They are also associated with lower reductions in viral load in the first week of therapy. Using in vitro short-term dose-response assays, these polymorphisms do not cause any reduction in sofosbuvir potency, suggesting an indirect mechanism of action in decreasing sofosbuvir efficacy. The identification of polymorphisms in NS2 and NS3 proteins associated with poor treatment outcomes emphasises the value of systematic genome-wide analyses of viruses in uncovering clinically relevant polymorphisms that impact treatment.

AB - Persistent hepatitis C virus (HCV) infection is a major cause of chronic liver disease, worldwide. With the development of direct-acting antivirals, treatment of chronically infected patients has become highly effective, although a subset of patients responds less well to therapy. Sofosbuvir is a common component of current de novo or salvage combination therapies, that targets the HCV NS5B polymerase. We use pre-treatment whole-genome sequences of HCV from 507 patients infected with HCV subtype 3a and treated with sofosbuvir containing regimens to detect viral polymorphisms associated with response to treatment. We find three common polymorphisms in non-targeted HCV NS2 and NS3 proteins are associated with reduced treatment response. These polymorphisms are enriched in post-treatment HCV sequences of patients unresponsive to treatment. They are also associated with lower reductions in viral load in the first week of therapy. Using in vitro short-term dose-response assays, these polymorphisms do not cause any reduction in sofosbuvir potency, suggesting an indirect mechanism of action in decreasing sofosbuvir efficacy. The identification of polymorphisms in NS2 and NS3 proteins associated with poor treatment outcomes emphasises the value of systematic genome-wide analyses of viruses in uncovering clinically relevant polymorphisms that impact treatment.

KW - Antiviral Agents/therapeutic use

KW - Genome, Viral/genetics

KW - Genotype

KW - Hepacivirus/drug effects

KW - Hepatitis C, Chronic/drug therapy

KW - Humans

KW - Polymorphism, Genetic

KW - Sofosbuvir/therapeutic use

KW - Treatment Failure

KW - Viral Load/drug effects

KW - Viral Nonstructural Proteins/genetics

UR - http://www.scopus.com/inward/record.url?scp=85119368220&partnerID=8YFLogxK

U2 - 10.1038/s41467-021-25649-6

DO - 10.1038/s41467-021-25649-6

M3 - Journal article

C2 - 34671027

VL - 12

SP - 1

EP - 11

JO - Nature Communications

JF - Nature Communications

SN - 2041-1723

IS - 1

M1 - 6105

ER -

ID: 68558504